AESCULAPIUS Farmaceutici

AESCULAPIUS Farmaceutici, also known simply as AESCULAPIUS, is an Italian pharmaceutical company. Specific details regarding its core pharmaceutical products, therapeutic areas, target markets, or operational scope beyond its Italian headquarters are not available in the provided source material. Similarly, explicit information concerning its scale, such as employee count beyond attacker claims, annual revenue figures, geographic reach, or notable facilities, is absent from the confirmed incident report.

The organisation is distinguished by its confirmed experience as a victim of a significant cybersecurity incident. In February 2023, AESCULAPIUS Farmaceutici suffered a ransomware attack perpetrated by the RansomHouse group. This attack involved the compromise of the company's IT infrastructure, leading to the exfiltration of sensitive internal data. Following reports that the company refused ransom demands, the RansomHouse group publicly released the stolen information on their darknet leak site. The published data reportedly included internal directories containing diverse company information, causing operational disruption. This incident highlights the company's exposure to sophisticated cyber threats employing double extortion tactics, demanding payment both for decryption keys and to prevent data publication. At the time of the incident reporting, no official statement from AESCULAPIUS appeared on its website addressing the attack or the criminal group's publication of stolen materials. Information regarding ownership structure or subsidiary relationships is not provided.